Development Pipeline
Detailed information on the research project currently underway. We encourage you to bookmark these pages and check back often. Updates will be added periodically with new information on status, newly-released data, and clinical trial results. Back to New Hair Loss Research Pipeline
Aclaris has teamed with JAKPharm LLC and Key Organics for the use of covalently binding, highly selective JAK3 inhibitor compounds for the treatment of hair loss. This technology could be useful not only for Alopecia Areata, but Androgenetic Alopecia as well.
JAK inhibition’s relation to hair loss was made by a team led by Dr. Angela Christiano. “We are delighted to enter into this agreement with Aclaris for the development of JAK inhibitors for alopecia areata, androgenetic alopecia, and other hair loss disorders,” said Dr. Christiano. “We look forward to Aclaris bringing JAK inhibitors to the clinic, particularly for Alopecia Areata.”
www.aclaristx.com
Passionate About Dermatology
09-19-16: New Study Confirms JAK3 Effective in Alopecia Areata 09-18-16: Alopecia Areata Cure? Aclaris Therapeutics JAK3 Inhibitors.
